Tyra Biosciences (NASDAQ:TYRA) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Tyra Biosciences (NASDAQ:TYRA) from a sell rating to a hold rating in a research note issued to investors on Sunday morning.

A number of other equities research analysts have also issued reports on the stock. Wedbush upped their price objective on shares of Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, Oppenheimer reissued an “outperform” rating and issued a $36.00 price target on shares of Tyra Biosciences in a research note on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $26.79 on Friday. Tyra Biosciences has a one year low of $6.42 and a one year high of $27.66. The stock has a market cap of $1.43 billion, a PE ratio of -14.33 and a beta of 1.07. The stock has a 50 day moving average price of $20.47 and a 200 day moving average price of $14.83.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). As a group, analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of the stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the completion of the transaction, the director owned 3,833,425 shares of the company’s stock, valued at $77,626,856.25. This trade represents a 6.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 15.20% of the stock is currently owned by company insiders.

Institutional Trading of Tyra Biosciences

Several hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. boosted its stake in shares of Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares during the period. SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the 3rd quarter worth approximately $133,000. Russell Investments Group Ltd. boosted its position in Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after buying an additional 2,766 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after buying an additional 1,668 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Tyra Biosciences in the second quarter worth $177,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.